Drug Type AAV based gene therapy |
Synonyms Alpha-1 antitrypsin deficiency gene therapy, RAAV1-CB-HAAT, Recombinant AAV-AAT vector gene therapy + [2] |
Target |
Mechanism A1AT stimulants(Alpha-1-antiproteinase stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alpha 1-Antitrypsin Deficiency | Phase 2 | US | 01 Jun 2010 | |
Alpha 1-Antitrypsin Deficiency | Phase 2 | US | 01 Jun 2010 | |
Alpha 1-Antitrypsin Deficiency | Phase 2 | IE | 01 Jun 2010 | |
Alpha 1-Antitrypsin Deficiency | Phase 2 | IE | 01 Jun 2010 |
Phase 2 | 9 | (Low Dose) | ljddsciuhi(yvwbnkdaab) = tshipuhsnc lxuxkvkywz (zvsutqvcdw, gugnmfiwuk - hxfarrglwv) View more | - | 14 Sep 2012 | ||
(Middle Dose) | ljddsciuhi(yvwbnkdaab) = qwqmnfdiln lxuxkvkywz (zvsutqvcdw, okcryodyor - wpviteeecf) View more |